A 3D Tour of Immuno-Oncology – Adverse Events

View Activity

PROGRAM CHAIR AND COURSE DIRECTORS

Arjun V. Balar, MD (Program Chair)
Assistant Professor of Medicine
Director, Genitourinary Medical
Oncology Program
NYU Perlmutter Cancer Center
NYU Langone Medical Center
New York, NY

Jeffery S. Weber, MD, PhD (Course Director)
Professor of Oncology
Department of Medicine
Perlmutter Cancer Center
NYU Langone Health
New York, NY

Vamsidhar Velcheti, MD (Course Director)
Director of Thoracic Medical Oncology
Perlmutter Cancer Center
NYU Langone Health
New York, NY

FACULTY SPEAKER

Isabella C. Glitza, MD, PhD
Assistant Professor
Department of Melanoma Medical Oncology
University of Texas
MD Anderson Cancer Center
Houston, TX

PROGRAM OVERVIEW

This case-based enduring activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Describe the pathophysiology of adult malignancies with a focus on tumor immunosurveillance and immune escape
  • Review the efficacy and most frequent irAEs associated with immune checkpoint inhibitors approved for use in different malignancies
  • Discuss the diagnosis, management, and monitoring of irAEs associated with immunotherapies
  • Identify best practices for the identification and management of irAEs in the emergency room setting

ACCREDITATION AND DESIGNATION STATEMENTS

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.00 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with cancer who are treated or eligible for treatment with immunotherapy.
Credits: 1.00 ANCC Contact Hour(s)

Accreditation Statement
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this Enduring activity for a maximum of 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Event UAN : JA4008163-9999-19-050-H04-P / JA4008163-9999-19-050-H04-T.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Balar has received consultant fees from Merck, Genentech, AstraZeneca, and Pfizer; fees for Non-CME/CE Services received directly from a commercial interest or its agent from Merck, Genentech, and AstraZeneca.
Dr. Weber has intellectual property or is a patent holder with Biodesix, has received consultant fees from BMS, Merck, Incyte, Celldux, Genentech, GSK, AstraZeneca, and Novartis; has ownership interests in Biomd, Alton, and Cytomx.
Dr. Velcheti has received consultant fees from BMS, Merck, Genentech, AstraZeneca, Celgene, Foundation Medicine, Nektar Therapeutics, Amgen, and Takeda Oncology.
Dr. Glitza serves on the speakers’ bureau for ARRAY; and received contracted research from BAS.

The independent reviewers, staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Brianna Hanson, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Deb Liao, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Lisa Dorin, Senior Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: April 29, 2019

EXPIRATION DATE: April 29, 2020

ENDURING MATERIAL LEARNER NOTIFICATION

A 3D View: Optimizing Immuno-Oncology Therapy Through the Management of Adverse Events

Date of CE Release: April 5, 2019
Date of CE Expiration: December 31, 2020
Location: Online

Acknowledgement of Financial Commercial Support

Bristol-Myers Squibb and Merck

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form to Med Learning Group.

Continuing Education Language Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this Enduring activity for a maximum of 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Event UAN : JA4008163-9999-19-050-H04-P / JA4008163-9999-19-050-H04-T.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Objectives – After attending this program you should be able to:

1. Describe the pathophysiology of adult malignancies with a focus on tumor immunosurveillance and immune escape
2. Review the efficacy and most frequent irAEs associated with immune checkpoint inhibitors approved for use in different malignancies
3. Discuss the diagnosis, management, and monitoring of irAEs associated with immunotherapies
4. Identify best practices for the identification and management of irAEs in the emergency room setting

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no relevant financial relationships.

Arjun Balar, Consultant Fees from Merck, Genentech, AstraZeneca, & Pfizer; fees for Non-CME/CE Services received directly from a commercial interest or its agent from Merck, Genentech, and AstraZeneca.
Isabella Glitza, Serves on the speakers’ bureau for ARRAY; and received contracted research from BAS.
Jeffery Weber, Has intellectual property or is a patent holder with Biodesix, has received consultant fees from BMS, Merck, Incyte, Celldux, Genentech, GSK, AstraZeneca, and Novartis; has ownership interests in Biomd, Alton, and Cytomx.
Vamsidhar Velcheti, Has received consultant fees from BMS, Merck, Genentech, AstraZeneca, Celgene, Foundation Medicine, Nektar Therapeutics, Amgen, and Takeda Oncology.

Contact Information
If you have questions regarding this enduring material activity, please contact us at bhanson@medlearninggroup.com

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.